Potential utility of L-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis

We examined the potential utility of L-carnitine for alleviating metabolic dysfunction-associated steatohepatitis (MASH) and preventing the development of hepatocellular carcinoma. Short-term L-carnitine administration ameliorated MASH through its anti-inflammatory effects. L-carnitine (2 g/day) was administered to 11 MASH patients for 10 weeks, and blood liver function tests were performed. Five patients received a serial liver biopsy, and liver histology and hepatic gene expression were evaluated using this tissue. 10-weeks L-carnitine administration significantly improved serum alanine transaminase and aspartate transaminase levels along with a histological improvement of the nonalcoholic fatty liver disease activity score, while steatosis and fibrosis were not improved. Gene expression profiling revealed a significant improvement of the inflammation and pro-fibrotic gene signature as well as the recovery of lipid metabolism. *** According to the submitter raw data are not available for this submission because the HDD was broken and we lost original CEL files. ***